Top

Published in:

01-04-2020 | Ureterectomy | Case report

A patient with synchronous bilateral low-grade upper tract urothelial carcinoma who underwent nephroureterectomy and total ureterectomy with ileal ureteric replacement

Authors: Yoshinori Matsuda, Takamitsu Inoue, Atsushi Maeno, Atsushi Koizumi, Ryohei Yamamoto, Taketoshi Nara, Sohei Kanda, Kazuyuki Numakura, Mitsuru Saito, Shintaro Narita, Shigeru Satoh, Tomonori Habuchi

Published in: International Cancer Conference Journal | Issue 2/2020

Abstract

We present the case of a synchronous bilateral low-grade upper-tract urothelial carcinoma patient who underwent left nephroureterectomy and right total ureterectomy with ileal ureteric replacement resulting in a favorable prognosis. A 66-year-old male presented with bilateral hydronephrosis. Computed tomography revealed left pelvic and right upper–middle ureteral tumors with no lymph node swelling or distant metastasis. The patient underwent a left nephroureterectomy with a bladder cuff, and histopathology revealed a low-grade urothelial carcinoma. Considering the contralateral low-grade nature as revealed in histopathology and the right retrograde ureterography being noninvasive, he underwent a right total ureterectomy with ileal ureteric replacement. Histopathology of the right ureter revealed a low-grade urothelial carcinoma. The patient successfully avoided an anephric status without renal function deterioration for 4 years with a transurethral resection for a recurrent small papillary bladder tumor on 18 months after the total ureterectomy.

Seisen T, Peyronnet B, Dominguez-Escrig JL et al (2016) Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel. Eur Urol 70:1052–1068CrossRef

Soria F, Shariat SF, Lerner SP et al (2017) Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 35:379–387CrossRef

Rouprêt M, Babjuk M, Burger M et al (2020) European Association of Urology guidelines on upper urinary tract urothelial carcinoma. Available via DIALOG. https://uroweb.org/guideline/upper-urinary-tract-urothelial-cell-carcinoma/#7

Bagrodia A, Kuehhas FE, Gayed BA et al (2013) Comparative analysis of oncologic outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract urothelial carcinoma. Urology 81:972–977CrossRef

Colin P, Ouzzane A, Pignot G et al (2012) French Collaborative National Database on U.U.T.-U.C. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int 110:1134–1141CrossRef

Lughezzani G, Jeldres C, Isbarn H et al (2009) Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer 45:3291–3297CrossRef

Fang D, Seisen T, Yang K et al (2009) A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma. EJSO 42:1625–1635CrossRef

Yakoubi R, Colin P, Seisen T et al (2014) Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: a meta-analysis and a systematic review of current evidence from comparative studies. Eur J Surg Oncol 40:1629–1634CrossRef

Jeldres C, Lughezzani G, Sun M et al (2010) Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol 183:1324–1329CrossRef

10.

Holmäng S, Johansson SL (2004) Synchronous bilateral ureteral and renal pelvic carcinomas: incidence, etiology, treatment and outcome. Cancer 15(101):741–747CrossRef

11.

Kang CH, Yu TJ, Hsieh HH et al (2004) Synchronous bilateral primary transitional cell carcinoma of the upper urinary tracts: ten patients with more than five years of follow-up. Urology 63:380–382CrossRef

12.

Fang D, Xiong G, Li X et al (2009) Incidence, characteristics, treatment strategies, and oncologic outcomes of synchronous bilateral upper tract urothelial carcinoma in the Chinese population. Urol Oncol 33:66.e1–66.e11CrossRef

13.

Mazeman E (1976) Tumours of the upper urinary tract calyces, renal pelvis and ureter. Eur Urol 2:120–126CrossRef

14.

Pedrosa JA, Masterson TA, Rice KR et al (2015) Oncologic outcomes and prognostic impact of urothelial recurrences in patients undergoing segmental and total ureterectomy for upper tract urothelial carcinoma. Can Urol Assoc J 9:E187–E192CrossRef

15.

Ou YC, Hu CY, Cheng HL et al (2018) Long-term outcomes of total ureterectomy with ileal-ureteral substitution treatment for ureteral cancer: a single-center experience. BMC Urol 18:73CrossRef

16.

Banerji JS, George AJ (2014) Total ureterectomy and ileal ureteric replacement for TCC ureter in a solitary kidney. Can Urol Assoc J 8:E938–E940CrossRef

17.

Pohar KS, Sheinfeld J (2001) When is partial ureterectomy acceptable for transitional-cell carcinoma of the ureter? J Endourol 15:405–408CrossRef

18.

Murphy DM, Zincke H, Furlow WL (1980) Primary grade 1 transitional cell carcinoma of the renal pelvis and ureter. J Urol 123:629–631CrossRef

19.

Giannarini G, Schumacher MC, Thalmann GN et al (2007) Elective management of transitional cell carcinoma of the distal ureter: can kidney-sparing surgery be advised? BJU Int 100:264–268CrossRef

20.

Campi R, Cotte J, Sessa F et al (2019) Robotic radical nephroureterectomy and segmental ureterectomy for upper tract urothelial carcinoma: a multi-institutional experience. World J Urol 37:2303–2311CrossRef

21.

Kato T, Nakayama R, Haba T et al (2018) Oncological and renal outcomes of segmental ureterectomy vs. radical nephroureterectomy for upper tract urothelial carcinoma. Oncol Lett 16:6861–6867PubMedPubMedCentral

22.

Cheng YT, Flechner SM, Chiang PH (2014) The role of laparoscopy-assisted renal autotransplantation in the treatment of primary ureteral tumor. Ann Surg Oncol 21:3691–3697CrossRef

23.

Armatys SA, Mellon MJ, Beck SD et al (2009) Use of ileum as ureteral replacement in urological reconstruction. J Urol 181:177–181CrossRef

24.

Chung BI, Hamawy KJ, Zinman LN et al (2006) The use of bowel for ureteral replacement for complex ureteral reconstruction: long-term results. J Urol 175:179–183CrossRef

25.

Verduyckt FJ, Heesakkers JP, Debruyne FM (2002) Long-term results of ileum interposition for ureteral obstruction. Eur Urol 42:181–187CrossRef

26.

Sim A, Todenhöfer T, Mischinger J et al (2014) Intracorporeal ileal ureter replacement using laparoscopy and robotics. Cent Eur J Urol 67:420–423

27.

Brandao LF, Autorino R, Zargar H et al (2014) Robotic ileal ureter: a completely intracorporeal technique. Urology 83:951–954CrossRef

28.

Chen H, Liu L, Pambuccian SE et al (2016) Urine cytology in monitoring recurrence in urothelial carcinoma after radical cystectomy and urinary diversion. Cancer Cytopathol 124:273–278CrossRef

29.

Flaig TW, Spiess PE, Agarwal N et al. (2020) National Comprehensive Cancer Network clinical practice guidelines in oncology-bladder cancer version3.2020-January 17. Available via DIALOG. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf

Title: A patient with synchronous bilateral low-grade upper tract urothelial carcinoma who underwent nephroureterectomy and total ureterectomy with ileal ureteric replacement
Authors: Yoshinori Matsuda
Takamitsu Inoue
Atsushi Maeno
Atsushi Koizumi
Ryohei Yamamoto
Taketoshi Nara
Sohei Kanda
Kazuyuki Numakura
Mitsuru Saito
Shintaro Narita
Shigeru Satoh
Tomonori Habuchi
Publication date: 01-04-2020
Publisher: Springer Singapore
Keywords: Ureterectomy
Ureterocutaneostomy
Computed Tomography
Computed Tomography
Urothelial Cancer
Urothelial Cancer
Published in: International Cancer Conference Journal / Issue 2/2020
Electronic ISSN: 2192-3183
DOI: https://doi.org/10.1007/s13691-020-00402-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab

A case of primary hepatic mucosa-associated lymphoid tissue lymphoma incidentally found in the sustained virological response state of chronic hepatitis C: review of the literature of this rare disease

Pancytopenia due to massive bone marrow carcinomatosis after radiotherapy for locally advanced breast cancer

Pancreatic cancer with leptomeningeal carcinomatosis: case report and literature review

Relief of eribulin-associated malaise by l-glutamine in two patients with uterine leiomyosarcoma: a case report

A case of chest wall recurrence of hilar cholangiocarcinoma 10 years after R1 surgery with positive ductal margin of carcinoma in situ

Keynote webinar | Spotlight on antibody–drug conjugates in cancer